TAVR is increasingly seen as the preferred option for symptomatic severe aortic stenosis, and clinical guidelines in the U.S. reserve their highest recommendations for patients who experience symptoms. Asymptomatic patients, meanwhile, are typically managed by clinical surveillance or a “watch and wait” approach; no symptoms means no treatment.

Hospitals could be turning away high-risk heart patients to help their TAVR programs receive a higher ranking, according to new research published in JACC: Cardiovascular Interventions. 

The recall was put in place after a hydrophilic coating was discovered on the inside of the devices. According to the FDA, patients treated with the catheters could face a number of significant risks. 

The Telltale system was designed to assist cardiologists when BASILICA is required prior to TAVR.

Performing M-TEER and T-TEER on the same patient using a single guide catheter appears to be both safe and effective. Researchers shared their experience with this approach in Circulation: Cardiovascular Interventions.

The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward. 

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Boston Scientific said two category III CPT codes are set to become permanent category I codes for physician payments starting Jan. 1, 2027.